Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD5L-engineered exosomes
- Development stage
- Preclinical
- Lead developer
- Zhongnan Hospital of Wuhan University
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CD5L-engineered exosomes (also known as CD5L-enriched FRC-Exos) are engineered extracellular vesicles (EVs) derived from fibroblastic reticular cells (FRCs) or CD5L-overexpressing cells, modified to deliver the anti-inflammatory and metabolic regulatory protein CD5L (CD5 antigen-like). These exosomes are further functionalized with a kidney-targeting LTH peptide, which binds to kidney injury molecule-1 (KIM-1/HAVCR1) on injured renal tubular cells. Developed by researchers at Zhongnan Hospital of Wuhan University, this therapeutic candidate is designed to treat sepsis-associated acute kidney injury (S-AKI). Mechanistically, the delivered CD5L interacts with fatty acid synthase (FASN) to inhibit fatty acid synthesis and promote fatty acid oxidation (FAO), thereby restoring mitochondrial bioenergetics and homeostasis. Additionally, the treatment promotes PINK1-Parkin-mediated mitophagy, inhibits NLRP3 inflammasome activation, and reduces tubular cell pyroptosis.
- Other names
- CD5L-enriched FRC-ExosCD-5L-enriched FRC-ExosCD 5L-enriched FRC-ExosCD5L-enriched exosomesCD-5L-enriched exosomesCD 5L-enriched exosomesLTH-modified CD5L-enriched FRC-Exoskidney-targeted fibroblastic reticular cell-derived and CD5L-enriched exosomes
02
Targets
FASN (Fatty acid synthase)TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)
Beyond the preview
Go deeper on CD5L-engineered exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD5L-engineered exosomes.